

4/21/04

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO . INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Known
				Filing Date	Herewith
				First Named Inventor	WEICHERT
				Group Art Unit	1624
				Examiner Name	T. TRUONG
Sheet	1	of	2	Attorney Docket Number	DEAV2003/0029 - US - NP

[illegible][illegible]

**Examiner
Signature**

Date Considered

4/9/06
5/5/05

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

2. 200

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	Not Yet Known	
			Filing Date	Herewith	
			First Named Inventor	WEICHERT	
			Group Art Unit	1624	
			Examiner Name	T. TRUONG	
Sheet	2	of	2	Attorney Docket Number	DEAV2003/0029 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	✓	DRIVER, et al., A Second-Generation Catalyst for Aryl Halide Amination: Mixed Secondary Amines from Aryl Halides and Primary Amines Catalyzed by (DPPF)PdCl ₂ , J. Amer. Chem Soc.; 118; 1996; pp.7217-7218.	
	✓	ENDRES, et al., Stroke Protection By 3-Hydroxy-3-Methylglutaryl (HMG) - CoA Reductase Inhibitors Medicated By Endothelial Nitric Oxide Synthase, Proc. Natl. Acad. Sci. USA, 95 (1998) 8880-8885 ,	
	✓	LI Huige et al., Activation of Protein Kinase C(alpha) and/or (epsilon) Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol., 1998, Vol. 53, pp 630-637 ,	
	✓	MARTIN-SANTAMARIA, et al., Synthesis and Stereochemistry of 11,11a-Dihydro Derivatives of (4S)-2,4-Dimethyl-2,4-dihydro-1H-pyrazino[2,1-b]quinoxaline-3,6-diones. A New Transannular Rearrangement Proposal., J. Org.Chem.; 64; 1999; pp.7233-7235.	
	✓	MOROI, et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury In Mice, J. Clin. Invest., 101 (1998) 1225-1232 ,	
	✓	NAKAYAMA Masafumi et al., T-786-->C Mutation in the 5'-Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated with Coronary Spasm, Clinical Investigation and Reports, Circulation 99, 1999, pp 2864-2870 ,	
	✓	SESSA, et al., Chronic Exercise In Dogs Increases Coronary Vascular Nitric Oxide Production And Endothelial Cell Nitric Oxide Synthase Gene Expression, Circ. Research 74 (1994) 349-353 ,	
	✓	YARENNE, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Hum. Gene Ther. 11 (2000) 1329-1338 ,	
TNT	✓	VOJKOVSKY, et al., Solid-Phase Synthesis of Heterocycles Containing an 1-Acyl-3-oxopiperazine Skeleton, J. Org. Chem.; 63; 1998; pp. 3162-3163.	

Examiner Signature		Date Considered	5/5/05
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

S.d 2